The psychedelic renaissance is in full swing. Long gone are the days where LSD or any other psychedelic was just reserved for the “turn on, tune in, and drop out” crowd. Now psychedelics have made it to the stock exchanges of the world and techie types in designer suits and ties are pouring tons of cash into psychedelic biomedical research: the study of how these substances can be used to heal us and ultimately the planet from lifelong and generational traumas. One of the ways psychedelics are being studied to heal us from our collective woes is through low dose use rather than the 12-hour pilgrimage into nature heroic dose that many may not have the 12 hours for or the grit for.
MindMed, one of the leaders in the biotech space and the first psychedelic company to go public on the Canadian Stock exchange in March of 2020 announced on January 12, 2021 that they will be commencing with an “innovative randomized placebo-controlled study evaluating the effects of daytime and evening administration of low doses of LSD on cognitive performance, sleep quality, mood, neuroplasticity markers, emotion regulation, quality of life, and immune system response.”
The study carried out through MindMed’s psychedelic Microdosing Division provides additional opportunities to integrate MindMeds’s newly formed digital medicine division known as Albert.
What is digital medicine or digital therapeutics? And why is it a big deal?
The methodology uses a variety of digital tools to manage, prevent, or treat psychological, behavioral, medical disorders or diseases. The delivery can be by way of an APP on one’s phone, watch, computer, or other wearable devices for instance.
When it comes to the psychedelic experience which begins with preparation and moves through integration pairing these devices with psychedelic assisted therapies can give the provider greater insights into the patient’s journey which can result in better outcomes in the overall therapeutic process.
The new study will be conducted in collaboration with Dr. Kim Kuypers of Maastricht University in the Netherlands.
“Dr. Kuypers, an authority on microdosing said, “I am excited about this new study which combines a variety of measures ranging from self-reporting and cognitive tasks to health and sleep parameters, bringing us closer to the mechanism of action behind the claimed benefits of microdosing.”
Author: Sherri Margolin
Disclaimer: Absolutely nothing you read in here should be taken as investment advice. The discussion of securities and ideas is never to be considered a recommendation to buy or sell any. Always do your own due diligence.